Viking Therapeutics Opens Second Maintenance Cohort as Obesity Race Shifts to Life After Weight Loss

Viking Therapeutics launched Part 2 of a VK2735 maintenance study, testing oral and injectable dosing, with data expected in 2027.

Viking Therapeutics has moved its obesity candidate VK2735 into the next stage of testing, launching Part 2 of an exploratory maintenance study that asks a question the weight-loss industry has largely sidestepped: how do patients hold onto their results once the pounds are gone?

The announcement drew a muted reception on the Frankfurt floor. Shares of the biotech changed hands 2.3 percent lower at EUR 25.50, with a separate reading putting the decline at 3.5 percent to EUR 25.20. Neither company statement nor market commentary pinned the move to a single catalyst, though the stock had already been under pressure in the run-up to the news.

Dosing Regimens Under the Microscope

The trial's central aim is to determine whether patients can defend a reduced weight without staying on the highest doses indefinitely. Viking is running daily and weekly oral administrations alongside biweekly and monthly subcutaneous injections, testing each maintenance approach after an initial 21-week run of weekly injections.

Roughly 195 adults are expected to enroll. Viking is guiding toward data from the cohort in 2027 — a timeline that offers little for traders focused on the next few quarters, but one that builds on earlier findings in which patients switched from weekly dosing after 21 weeks to less frequent schedules. During that prior 12-week phase, participants on biweekly dosing retained up to 97 percent of their earlier weight loss, while the monthly injection group held onto as much as 90 percent.

A Financing Round That Reshaped the Share Count

Funding the expanding clinical program is no small undertaking, and Viking addressed that roughly a week ago by closing a combined equity and convertible offering. The company placed 9,035,714 common shares at USD 35.00 apiece and issued USD 258.75 million in senior convertible notes carrying a 2.00 percent coupon and maturing in 2032. Gross proceeds from the upsized transactions came to about USD 575 million, translating into an estimated net inflow of roughly USD 547.8 million.

That capital cushion underpins the pipeline work. For existing holders, however, the issuance brought meaningful dilution — a factor that had already weighed on the stock before the current study update. Since the raise closed, the shares have shed 9.1 percent.

Patience as the Real Currency

The competitive logic behind maintenance therapy is straightforward. A reliable strategy for keeping weight off — whether through a pill or an infrequent injection — would remove a major obstacle to broader adoption of obesity treatments, giving patients the flexibility they want and payers the durable, tolerable options they demand.

Viking's decision to push into maintenance regimens signals strategic foresight, yet the payoff sits years down the road. With fresh liquidity in hand, the company can advance its clinical phases toward the hoped-for 2027 readout without immediate financial strain. For investors, the takeaway is less about today's headline than about the distance still to travel before hard proof arrives.